Creative Biolabs is accelerating gene therapy research globally with specialized expertise. SHIRLEY, NY, UNITED STATES, ...

Eli Lilly (NYSE:LLY) announced the acquisition of Orna Therapeutics to expand into circular RNA based gene and autoimmune ...

Circular Genomics, a molecular diagnostics company pioneering circular RNA (circRNA)–based biomarkers for neurodegenerative disease, today announced the completion of exclusive intellectual property ...

Diabetic foot ulcers are slow-healing and increase the risk of infections and amputation. Researchers at Karolinska ...

Deep within our nerve cells, a molecule is at work that has no beginning and no end. Instead of a straight chain, as is common for most RNA strands, it forms a closed loop. Known as circular RNAs ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing agreement Altamira Therapeutics Ltd.

Over the past few decades, RNA’s place in biology has transformed from being a mere intermediate between DNA and protein to a fascinating molecule with diverse activities that go well beyond simple ...

Eli Lilly (LLY) has agreed to acquire biotechnology company Orna Therapeutics for up to $2.4B in cash, inclusive of an ...

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, ...